| Field | Specification |
|---|---|
| Target | |
| Alternative names | Tumor necrosis factor receptor superfamily member 4;ACT35 antigen;OX40L receptor;TAX transcriptionally-activated glycoprotein 1 receptor;CD134;TNFRSF4;TXGP1L; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human CD134/OX40, different from the related mouse sequence by ten amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets tumor necrosis factor receptor superfamily member 4 (gene TNFRSF4) in human samples and is validated for flow cytometry, IHC, ICC/IF and Western blot. The predicted molecular weight is 29.3 kDa, and the supplier reports an observed band at about 50 kDa.
OX40 (TNFRSF4, CD134) is a costimulatory receptor expressed on activated T cells that binds OX40 ligand (TNFSF4). Its signals support T-cell survival, expansion and the formation of long-lived memory, so OX40 is widely studied in adaptive immunity, autoimmunity and cancer immunotherapy research. It also serves as an entry receptor for human herpesvirus 6B.
| Target | Tumor necrosis factor receptor superfamily member 4 (gene TNFRSF4; UniProt P43489, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 29.3 kDa |
| Observed MW | 50 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
|---|---|
| Western blot | 0.1–0.5 µg/mL (Human) |
| IHC (frozen sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 0.5–1 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): SW620 cells, 22RV1 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human tonsil tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with a confirmed signal (flow cytometry): human PBMC cells.
Immunogen
Synthetic peptide from the C-terminal region of human CD134/OX40. It differs from the mouse sequence at ten residues.
Reactivity Notes
The supplier lists reactivity with human. UniProt places tumor necrosis factor receptor superfamily member 4 in the membrane. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
